Impact of Docetaxel and Cabazitaxel on circulating neuroendocrine markers in castration resistant prostate cancer

Trial Profile

Impact of Docetaxel and Cabazitaxel on circulating neuroendocrine markers in castration resistant prostate cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2016

At a glance

  • Drugs Cabazitaxel (Primary) ; Docetaxel (Primary)
  • Indications Prostate cancer
  • Focus Biomarker; Pharmacodynamics
  • Acronyms NEUTAX
  • Most Recent Events

    • 16 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 27 Mar 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top